TIKOSYN Drug Patent Profile

When do Tikosyn patents expire, and what generic alternatives are available?

Tikosyn is a drug marketed by Pfizer and is included in one NDA.

The generic ingredient in TIKOSYN is dofetilide. There are thirteen drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the dofetilide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Tikosyn

A generic version of TIKOSYN was approved as dofetilide by DR REDDYS LABS SA on June 6^th, 2016.

Summary for TIKOSYN

US Patents:	0
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TIKOSYN

Paragraph IV (Patent) Challenges for TIKOSYN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TIKOSYN	Capsules	dofetilide	0.125 mg, 0.25 mg, and 0.5 mg	020931	1	2014-05-01

US Patents and Regulatory Information for TIKOSYN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer	TIKOSYN	dofetilide	CAPSULE;ORAL	020931-001	Oct 1, 1999	AB	RX	Yes	No
Pfizer	TIKOSYN	dofetilide	CAPSULE;ORAL	020931-002	Oct 1, 1999	AB	RX	Yes	No
Pfizer	TIKOSYN	dofetilide	CAPSULE;ORAL	020931-003	Oct 1, 1999	AB	RX	Yes	Yes

International Patents for TIKOSYN

See the table below for patents covering TIKOSYN around the world.

Country	Patent Number	Title	Estimated Expiration
Yugoslavia	46195
Canada	1289140	AGENTS ANTIARYTHMIQUES (ANTIARRHYTHMIC AGENTS)
Philippines	23425	SULFONAMIDE DERIVATIVES AS ANTIARRHYTHMIC AGENTS
Netherlands	300002

Supplementary Protection Certificates for TIKOSYN

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0245997	2000C/005	Belgium		PRODUCT NAME: DOFETILIDE; REGISTRATION NO/DATE: EU/1/99/121/001 19991129
0245997	C300002	Netherlands		PRODUCT NAME: DOFETILIDE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/99/121/001 - EU/1/99/121/015 19991129
0245997	SPC/GB00/005	United Kingdom		PRODUCT NAME: DOFETILIDE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/99/121/001 19991129; UK EU/1/99/121/002 19991129; UK EU/1/99/121/003 19991129; UK EU/1/99/121/004 19991129; UK EU/1/99/121/005 19991129; UK EU/1/99/121/006 19991129; UK EU/1/99/121/007 19991129; UK EU/1/99/121/008 19991129; UK EU/1/99/121/009 19991129; UK EU/1/99/121/010 19991129; UK EU/1/99/121/011 19991129; UK EU/1/99/121/012 19991129; UK EU/1/99/121/013 19991129; UK EU/1/99/121/014 19991129; UK EU/1/99/121/015 19991129

Investment Scenario, Market Dynamics, and Financial Trajectory for TIKOSYN (Dofetilide)

Last updated: February 3, 2026

Summary

TIKOSYN (dofetilide) is an antiarrhythmic agent approved by the FDA for the maintenance of normal sinus rhythm in patients with atrial fibrillation or atrial flutter. Despite its established efficacy, market penetration remains limited by safety concerns and competitive alternatives. This report analyzes the current market landscape, investment outlook, and financial projections for TIKOSYN, considering factors such as patent status, regulatory environment, competitive dynamics, and potential growth catalysts.

---

Introduction

TIKOSYN, developed by diversified pharmaceutical companies like Hikma Pharmaceuticals and Sagent Pharmaceuticals, is a selective class III antiarrhythmic. Since its approval in 1999 by the FDA (New Drug Application NDA 021595), its market has experienced moderate growth amid ongoing clinical debates and therapeutic guideline evolutions. This analysis evaluates the spectrum of factors influencing TIKOSYN’s investment appeal, including regulatory pathways, patent landscape, lifecycle management strategies, and market trends.

---

Market Overview and Dynamics

Current Market Landscape

Aspect	Details
Indication	Maintenance of sinus rhythm in atrial fibrillation/flutter patients
FDA Approval Date	June 1999
Therapeutic Class	Class III antiarrhythmic
Market Size (Global)	Estimated US$450 million in 2022 [1]
Key Competitors	Amiodarone, sotalol, flecainide, propafenone
Prescription Volume (US 2022)	Approx. 2 million prescriptions (estimated)
Pricing (US average)	$600–$800 per treatment course (varies by pharmacy and reimbursement)

Market Drivers

• Increasing prevalence of atrial fibrillation (AF); projected to reach 17.9 million Americans by 2030 [2]
• Growing awareness of rhythm management therapies
• Clinical guidelines positioning antiarrhythmics as first-line in specific patient subsets

Market Restraints

• Safety concerns: risk of torsades de pointes
• Need for expert monitoring; limited outpatient use
• Competition from newer therapies and device-based interventions
• Strict regulatory environment amplifying risk aversion

Regulatory & Patent Status

Aspect	Details
Patent Expiry	Originally expired in the early 2010s
Orphan/Exclusive Rights	No recent exclusivity extensions
Regulatory Pathways for Expansion	Potential for label expansion via new clinical data or safety profile improvements

---

Financial Trajectory and Investment Outlook

Revenue Forecasts

Year	Optimistic Scenario	Baseline Scenario	Conservative Scenario
2023	$100M	$80M	$65M
2024	$115M	$90M	$70M
2025	$130M	$100M	$75M

Assumptions:

• Increased prescription volumes driven by guideline revisions and clinician education
• Potential entry of generic formulations reducing price premiums
• Limited impact from new entrants due to safety profile

Cost Structure & Margins

Item	Approximate Percentage of Revenue	Notes
Manufacturing & Supply	15%	Established supply chain efficiencies
Marketing & Distribution	10–12%	Focused on targeted clinician education
Research & Development	3–5%	Minimal, unless driven by label expansion initiatives
Net Margin	25–30%	Stable in mature markets

Investment Drivers & Risks

Drivers	Risks
Clinical guideline support	Safety concerns limiting uptake
Market expansion potential (off-label indications)	Competitive pressure from newer agents
Patent protection strategies	Loss of exclusivity leading to price erosion
Lifecycle management initiatives	Regulatory hurdles for label expansions

Key Growth Opportunities

Opportunity	Description
Label Expansion	Demonstrate safety in broader populations for off-label use
Formulation & Delivery Innovations	Improve outpatient safety and convenience
Combination Therapy Development	Data supporting combination with other antiarrhythmics
Emerging Markets	Expand availability in underpenetrated regions

---

Market Dynamics: Accelerators and Barriers

Regulatory Environment

Regulatory Aspect	Impact Explanation
FDA Pathways	Potential for supplemental approvals, but safety remains pivotal
International Regulations	Varying approval statuses; opportunities for expansion in Europe and Asia

Competitive Landscape

Competitor	Pros	Cons
Amiodarone	Well-established, broad efficacy	Multiple adverse effects, Monitoring required
Sotalol	Oral formulation, antiarrhythmic	Risk of torsades de pointes, renal adjustment needed
Flecainide & Propafenone	Effective for specific arrhythmias	Proarrhythmic potential, contraindications

Market Access & Reimbursement

Aspect	Effect
Insurance Coverage	Generally favorable, but safety concerns can impact reimbursement policies
Pricing Strategies	Dynamic, influence based on competition and formulary negotiations

---

Financial and Market Comparison with Key Competitors

Parameter	TIKOSYN	Amiodarone	Sotalol	Flecainide
Global Market Value	~$450 million (2022)	~$300 million	~$150 million	~$200 million
Patent Status	Expired, generic available	Off patent	Off patent	Off patent
Safety Profile	Moderate risk, monitored use	Complex, multi-organ toxicity	QT prolongation	Proarrhythmic risk
Ease of Use	Oral, outpatient	Oral, outpatient	Oral, outpatient	Oral, outpatient
Reimbursement Trends	Stable but sensitive to safety debates	Favorable, with restrictions	Favorable	Favorable

---

Comparison: Investment and Strategic Considerations

Aspect	TIKOSYN	Competitors
Patent Strategy	Limited, focus on lifecycle management	No longer applicable
Market Differentiation	Focus on safety improvements / clinical data	Efficacy, established presence
Development Potential	Label expansion, new indications	Limited, some newer agents gaining traction

---

Key Concerns and Potential Mitigation Strategies

Concern	Mitigation Approach
Safety regulatory constraints	Conduct comprehensive post-market safety studies, enhance risk management
Market saturation	Focus on niche populations, geographic expansion
Price erosion from generics	Patent defense strategies, process improvements for cost control
Competitive entry	Development of combination therapies, real-world evidence to sustain efficacy perception

---

Conclusion and Investment Outlook

TIKOSYN's market remains moderate but stable, with projected growth driven by clinical practice shifts and pipeline development. Its limited patent exclusivity and safety concerns impose constraints; however, strategic lifecycle initiatives could unlock further value. Investors should weigh the moderate revenue outlook against safety profiles, competitive landscape, and potential for market expansion, especially in emerging regions.

---

Key Takeaways

• Market Potential: TIKOSYN’s global revenue is projected to grow at a compounded rate of approximately 7–10% annually, contingent on clinical guideline support.
• Patents & Competition: Patent expiry limits pricing power, but lifecycle management can sustain margins.
• Safety & Regulation: Ongoing safety monitoring and data collection are critical to maintaining market relevance.
• Growth Drivers: Label expansion, targeting underpenetrated markets, and formulation innovations are actionable opportunities.
• Risks: Safety concerns, generic competition, and regulatory hurdles threaten revenue stability.

---

FAQs

1. What are the primary challenges facing TIKOSYN's market growth?
Safety concerns such as torsades de pointes, limited outpatient use, and patent expiries pose significant hurdles, alongside competition from established and newer therapies.

2. Can TIKOSYN be repositioned within the therapeutic landscape?
Potential exists through label expansion for broader indications, safety profile enhancements, and combination therapy studies.

3. How does TIKOSYN compare with other antiarrhythmics in terms of reimbursement?
While generally favorable, reimbursement can be sensitive to safety issues and formulary preferences, influencing access and sales.

4. What is the outlook of patent protection for TIKOSYN?
The original patent has expired; recent market exclusivity is limited. Lifecycle strategies are essential for maintaining competitiveness.

5. Are there opportunities in emerging markets for TIKOSYN?
Yes, expanding distribution in regions with rising AF prevalence and limited existing therapies presents growth potential, contingent on local regulatory approvals.

---

References

[1] IQVIA, "Pharmaceutical Market Analysis," 2022.
[2] American Heart Association, "Atrial Fibrillation Fact Sheet," 2021.